Junshi Biosciences has established a diversified R&D pipeline comprising 28innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurologic, and infectious diseases. The Company was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China and clinical trial application approval for anti-PCSK9 monoclonal antibody from NMPA. The world's first in human anti-BTLA antibody for solid tumors was officially approved for clinical trials by the FDA and the NMPA. From this year onwards, Junshi Biosciences pooled its efforts with Chinese science institutions to co-develop JS016, China's first neutralizing human monoclonal antibodies against SARS-CoV-2, that has entered Phase Ib/II clinical trials, part of our continuous innovation for disease control and prevention in China and beyond.

Junshi Biosciences has independently developed and established an integrated technology system covering the entire lifecycle of protein drugs from early R&D to industrialization. The system involves seven technology platforms, which are (i)automated high-efficiency screening platform for antibody selection and functional assays, (ii)high-yielding stable expression cell lines screening and establishment platform, (iii) antibody humanization and construction platform, (iv)CHO cell fermentation process development platform, (v)antibody purification process development and formulation optimization platform, (vi)human transmembrane receptor protein array and high-throughput screening platform and (vii)antibody quality research, control and assurance platform. Meanwhile, a globally integrated R&D process has been established. With four R&D centers worldwide, the Company has outstanding ability to discover and develop innovative biologics drugs, including key steps, i.e. independent target assessment, mechanism study and validation, clinical drug screening and functional validation, etc. In regard to production, the Company has two monoclonal antibody production bases with combined 33,000L fermentation capacity in China, located in Suzhou Wujiang and Shanghai Lingang. The two established manufacturing infrastructures can support commercialization and provide our partners and patients with high quality products through a global supply chain network.